Transcript levels of AR-V7 target genes (UBE2C, CDC20, Akt1, CYCLIN 2A) were normalized to transcript levels of RPL13a housekeeping gene. effect on proliferation of enzalutamide-resistant cells was achieved with a combination of ralaniten compounds with ionizing radiation. Ralaniten and EPI-7170 sensitized prostate cancer cells that express full-length AR and AR-Vs to radiotherapy whereas enzalutamide had no added benefit. = 4 impartial experiments. * 0.05, ** 0.01, **** 0.0001; Two-way ANOVA with Tukeys multiple comparison correction. (E) AR-V7 transcriptional activity in LNCaP cells ectopically expressing AR-V7 and transfected with a reporter regulated by AR-V7 binding sites (V7BS3-luciferase). Cells were incubated with ENZA (5 M), EPI-002 (35 M), EPI-7170 (5 M), or vehicle (DMSO) for 24 h. (F) EPI-7170 inhibits expression of endogenous genes regulated by full-length AR. LNCaP95 cells were pretreated with ENZA (10 M), EPI-002 (25 M), and EPI-7170 (10, 5, and 2.5 M) prior to the addition of R1881 (1 nM), or vehicle, and incubated for an additional 48 h. Transcript levels of full-length AR target genes (PSA/KLK3, FKBP5, TMPRSS2, NKX3.1) were normalized to transcript levels of RPL13a. Bars represent the mean SEM of = 3 impartial experiments. (G) EPI-7170 inhibits expression of endogenous genes regulated by AR-V7. LNCaP95 cells were treated with ENZA (10 M), EPI-002 (25 M), and EPI-7170 (10, 5, and 2.5 M) in the absence of androgen for 48 h. Transcript levels of AR-V7 target Azilsartan D5 genes (UBE2C, CDC20, Akt1, CYCLIN 2A) were normalized to transcript levels of RPL13a housekeeping gene. Bars represent the mean SEM of = 3 impartial experiments. PSA(6.1kb)-luciferase and probasin (PB)-luciferase reporters are highly induced by androgen via ligand-bound full-length AR binding to androgen-response elements (AREs) within the enhancer and promoter regions of these reporters. In LNCaP human prostate cancer Azilsartan D5 cells that express functional full-length AR, an IC50 for EPI-7170 was measured at 1.08 0.55 M compared to 9.64 3.72 M for ralaniten to inhibit androgen-induced PSA-luciferase activity (Physique 1B). Antiandrogens were potent as expected against androgen-induced transcriptional activity of full-length AR. Enzalutamide had an IC50 of 0.12 0.04 M; bicalutamide 0.15 Col4a5 0.10 M; and consistent with apalutamide not working well around the mutated T877A mutation in the AR-LBD in this cell line, it had an IC50 of 4.42 1.57 M. Ralaniten inhibits the transcriptional activities of full-length AR and truncated AR and AR-Vs lacking LBD that include AR1-653, AR-V7, and AR-V567es [11,33,34]. To ensure that the modifications to the chemical scaffold of EPI-7170 also had improved potency against the transcriptional activity of AR-V7 and in mixed populations of full-length AR and AR-Vs, robust levels of AR-V7 were ectopically expressed in LNCaP cells (Physique 1C). Equimolar concentrations of enzalutamide (5 M) and EPI-7170 (5 M) both effectively blocked androgen-induced transcriptional activity of full-length AR as Azilsartan D5 measured using the PB-luciferase reporter (Physique 1D). Enzalutamide had no effect on AR-V7-induced transcriptional activity in the absence of androgen as expected, whereas EPI-7170 attenuated the transcriptional activity of AR-V7 (Physique 1D, middle panel). In the presence of androgen and ectopic expression of AR-V7 (Physique 1D, right panel), enzalutamide reduced PB-luciferase activity induced by full-length AR but had no effect on levels of transcription induced by AR-V7. EPI-7170 was effective at blocking the transcriptional activities of both full-length AR and AR-V7 regardless of androgen. To isolate the transcriptional activity of AR-V7, we employed the highly specific V7BS3-luciferase reporter that contains three AR-V7 binding sites linked in tandem in front of a minimal promoter [35]. This reporter is usually Azilsartan D5 specific for AR-V7 with no binding sites for the full-length AR [35]. Activity of the reporter was dependent upon expression of AR-V7 and could not be blocked by enzalutamide (5 M; Physique 1E). Both ralaniten (35 M) and 7-fold less EPI-7170 (5 M) were effective at blocking the transcriptional activity of AR-V7. To ensure that EPI-7170 blocked endogenous gene expression driven by full-length AR and AR-Vs, LNCaP95 human prostate cancer cells that express both functional full-length AR and AR-Vs were utilized [12,28,36]. Androgen-induced levels of KLK3/PSA, FKBP5, TMPRSS2, and NKX3.1 transcripts were all inhibited by enzalutamide, ralaniten, and EPI-7170 (Physique 1F). Azilsartan D5 EPI-7170 was as effective or better at inhibiting androgen-induced.